Merkliste
Die Merkliste ist leer.
Der Warenkorb ist leer.
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.

Analogue-based Drug Discovery

BuchGebunden
CHF237.00

Beschreibung

The easiest way to create a new drug is to modify an existing one. These so-called drug analogs account for about half of all "new" drugs and are of tremendous importance both for medical and financial reasons. In addition, drug analogs can be modeled on naturally occurring bioactive substances that do not make good drugs on their own, thereby considerably increasing the therapeutic range of pharmaceutical medicine.This first authoritative and systematic overview of past and current strategies for successful drug development by modification spans all important drug classes and all major therapeutic fields. It discusses analog-based drug discovery for, among others, beta-blockers, ACE inhibitors, steroids, opiates, coxibs, stigmines, proton pump inhibitors, platinum compounds and quinolones. In addition, case studies on selected commercially successful drug analogs provide prime advice for new drug development projects based on modification.The book is rounded off with an exclusive table of the 1,000 most successful drug analogs according to IMS ranking, classified in terms of chemical structure, mode of action and patentability.Officially endorsed by the International Union of Pure and Applied Chemistry's Drug Development Committee, indispensable for medicinal and pharmaceutical chemists in all fields.
Weitere Beschreibungen

Details

ISBN/GTIN978-3-527-31257-3
ProduktartBuch
EinbandGebunden
Verlag
Erscheinungsdatum20.01.2006
Auflage1. Auflage
Seiten606 Seiten
SpracheEnglisch
MasseBreite 170 mm, Höhe 240 mm, Dicke 36 mm
Gewicht1164 g
Illustrationenschwarz-weiss Illustrationen, Tabellen, schwarz-weiss
Artikel-Nr.1986839
Verlagsartikel-Nr.1131257 000
KatalogBuchzentrum
Datenquelle-Nr.1687289
Weitere Details

Autor

Janos Fischer is research laboratory head at Richter Ltd. (Budapest, Hungary). He received his education in Hungary with B.Sc. and P.h. D. degrees in organic chemistry at the Eotvos University of Budapest with Professor A. Kucsman. Between 1976-78 he was a Humboldt fellow at the University of Bonn with Professor W. Steglich. He has worked at Richter Ltd. since 1981 where he participated in the research and development of leading cardiovascular drugs in Hungary. His main interest now is analog-based drug discovery. He is author of some 100 patents and scientific publications. In 2004 he was elected member of the Chemistry and Human Health Division of IUPAC. Robin Ganellin studied Chemistry at London University, receiving a PhD in 1958 under Professor Michael Dewar, and was a Research Associate at MIT with Arthur Cope in 1960. He then joined Smith Kline & French Laboratories in the UK and was one of the co-inventors of the revolutionary drug cimetidine (also known as Tagamet). In 1986 he was made a Fellow of the Royal Society and appointed to the SK&F Chair of Medicinal Chemistry at University College London, where he is now Emeritus Professor of Medicinal Chemistry. Professor Ganellin is co-inventor on over 160 patents and has authored 250 scientific publications. He was President of the Medicinal Chemistry Section of IUPAC and is currently Chairman of the IUPAC Subcommittee on Medicinal Chemistry and Drug Development.

Schlagworte